Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Equivalence: In Vitro and In Vivo Bioequivalence01:17

Equivalence: In Vitro and In Vivo Bioequivalence

236
Body:Bioequivalence studies are crucial in evaluating whether new drugs can match an approved one regarding pharmacological effects and clinical performance. These studies test if drugs, despite different dosage forms, share identical plasma concentration-time profiles. Three types of equivalence are central to these studies: chemical, pharmaceutical, and therapeutic. Chemical equivalence indicates that two or more drug products contain identical active ingredients in equal amounts.
236
Bioequivalence studies: Biowaivers01:13

Bioequivalence studies: Biowaivers

272
Body:In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
272
Bioequivalence Data: Statistical Interpretation01:16

Bioequivalence Data: Statistical Interpretation

225
Body:The statistical interpretation of bioequivalence data is a significant aspect of pharmaceutical research. Bioequivalence refers to the absence of any significant difference in the rate and extent to which the active ingredient in pharmaceutical products becomes available at the site of drug action when administered at the same molar dose under similar conditions. This helps determine if different drug products have similar absorption rates, ensuring their interchangeability.Statistical...
225
Bioequivalence of Drugs: Drugs with Multiple Indications01:09

Bioequivalence of Drugs: Drugs with Multiple Indications

162
The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each...
162
Bioequivalence: Overview01:16

Bioequivalence: Overview

2.0K
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
2.0K
Sampling Continuous Time Signal01:11

Sampling Continuous Time Signal

755
In signal processing, a continuous-time signal can be sampled using an impulse-train sampling technique, followed by the zero-order hold method. Impulse-train sampling involves the use of a periodic impulse train, which consists of a series of delta functions spaced at regular intervals determined by the sampling period. When a continuous-time signal is multiplied by this impulse train, it generates impulses with amplitudes corresponding to the signal's values at the sampling points.
In the...
755

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Molecular cloning and three-dimensional structure modelling of HLA-DRalpha * 0101, DRbeta1 * 04051 and DRbeta1 * 07011].

Zhongguo ying yong sheng li xue za zhi = Zhongguo yingyong shenglixue zazhi = Chinese journal of applied physiology·2010
Same author

[Cloning of B7-1 and B7-2 genes from human Burkitt's B lymphocyte line].

Zhongguo ying yong sheng li xue za zhi = Zhongguo yingyong shenglixue zazhi = Chinese journal of applied physiology·2010
Same author

Horny Verrucoma of the Foot, Remarkable for the Size and Variety of Dyskeratosis Lesions, Cancer-like Cells and Abundance of Mitosis, in a Patient Elsewhere with Multiple Epitheliomatosis and Horn Papilloma of the Face

Dermatologica·2010
Same author

Fibroma in Civatte tablet.

Dermatologica·2010
Same author

Bowen's disease; Erythroplasia of the mucous membranes.

Dermatologica·2010
Same author

Parkes Weber's hypertrophic herniagiectasia.

Dermatologica·2010
Same journal

Correction.

Journal of biopharmaceutical statistics·2026
Same journal

Leveraging external controls in clinical trials: estimands, estimation, assumptions.

Journal of biopharmaceutical statistics·2026
Same journal

Special issue of nonclinical statistics in regulatory applications guest editors' notes.

Journal of biopharmaceutical statistics·2026
Same journal

Comparison of flexible parametric modeling and nonparametric methods to estimate restricted mean survival time: A simulation study.

Journal of biopharmaceutical statistics·2026
Same journal

Simulated treatment comparisons with jackknife pseudo values for estimating population-adjusted marginal treatment effects.

Journal of biopharmaceutical statistics·2026
Same journal

Sample sizes for randomized controlled trials utilizing Bayesian response adaptive randomization for continuous outcomes.

Journal of biopharmaceutical statistics·2026
See all related articles

Related Experiment Video

Updated: Feb 7, 2026

Optimizing Sample Preparation for Cryogenic Electron Microscopy
06:32

Optimizing Sample Preparation for Cryogenic Electron Microscopy

Published on: April 11, 2025

1.0K

Optimal sampling times in bioequivalence tests.

F H Kong1, R Gonin

  • 1Westat, Rockville, Maryland 20850, USA.

Journal of Biopharmaceutical Statistics
|March 10, 2000
PubMed
Summary
This summary is machine-generated.

Optimizing blood collection times in bioequivalence studies improves drug formulation analysis. This new method enhances the accuracy of estimating the area under the concentration-time curve (AUC) for bioavailability.

More Related Videos

Morris Water Maze Test: Optimization for Mouse Strain and Testing Environment
10:24

Morris Water Maze Test: Optimization for Mouse Strain and Testing Environment

Published on: June 22, 2015

22.5K
Test Samples for Optimizing STORM Super-Resolution Microscopy
16:52

Test Samples for Optimizing STORM Super-Resolution Microscopy

Published on: September 6, 2013

31.6K

Related Experiment Videos

Last Updated: Feb 7, 2026

Optimizing Sample Preparation for Cryogenic Electron Microscopy
06:32

Optimizing Sample Preparation for Cryogenic Electron Microscopy

Published on: April 11, 2025

1.0K
Morris Water Maze Test: Optimization for Mouse Strain and Testing Environment
10:24

Morris Water Maze Test: Optimization for Mouse Strain and Testing Environment

Published on: June 22, 2015

22.5K
Test Samples for Optimizing STORM Super-Resolution Microscopy
16:52

Test Samples for Optimizing STORM Super-Resolution Microscopy

Published on: September 6, 2013

31.6K

Area of Science:

  • Pharmacokinetics
  • Bioavailability studies
  • Biostatistics

Background:

  • Bioequivalence studies compare drug formulations using bioavailability parameters like AUC, Cmax, and tmax.
  • Accurate measurement of these parameters is crucial for reliable bioequivalence testing.
  • Limited blood draws necessitate optimized sampling times for precise pharmacokinetic profiling.

Purpose of the Study:

  • To develop an optimization approach for determining optimal blood collection schedules in bioequivalence studies.
  • To enhance the accuracy of estimating key bioavailability parameters from limited sampling points.
  • To provide a method applicable to various compartmental models.

Main Methods:

  • An optimization approach was developed to calculate optimal time designs for pharmacokinetic studies.
  • The method was applied to one-compartment models but is generalizable to other compartmental models.
  • Simulations were used to evaluate the performance of the proposed optimal design.

Main Results:

  • The proposed optimal time design significantly improves the accuracy of estimating the area under the concentration-time curve (AUC).
  • The optimization approach ensures more reliable bioavailability parameter estimation despite limited blood sampling.
  • The method's generalizability allows for its application across different pharmacokinetic models.

Conclusions:

  • Optimized blood sampling schedules are essential for accurate bioequivalence assessments.
  • The developed optimization approach offers a robust method for designing efficient pharmacokinetic studies.
  • This strategy enhances the precision of bioavailability parameter estimation, particularly AUC.